SA国际传媒

Sunday 27 September 2026
Salisbury Foundation Trust

FOI_9596

Internal Reference Number: FOI_9596

Date Request Received: 03/08/2026 00:00:00

Date Request Replied To: 21/08/2026 00:00:00

This response was sent via: By Email

Request Summary: Atopic Dermatitis

Request Category: Researcher



 
Question Number 1:
How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products:

鈥� Abrocitinib

鈥� Acitretin

鈥� Alitretinoin

鈥� Azathioprine

鈥� Baricitinib

鈥� Ciclosporin

鈥� Dupilumab

鈥� Lebrikizumab

鈥� Methotrexate

鈥� Mycophenolate mofetil

鈥� Pimecrolimus

鈥� Phototherapy (UVB or PUVA) - for Atopic Dermatitis only

鈥� Tacrolimus ointment

鈥� Tralokinumab

鈥� Upadacitinib

鈥� Nemolizumab
 
Answer To Question 1:
Please see our response to all questions in the spreadsheet attached.

To accompany this answer to question 1 please also see the documents listed below:

 13916 - FOI_9596 - Atopic Dermatitis.xlsx
 
Question Number 2:
In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

鈥� Abrocitinib

鈥� Baricitinib

鈥� Dupilumab

鈥� Lebrikizumab

鈥� Tralokinumab

鈥� Upadacitinib

鈥� Nemolizumab

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen
 
Answer To Question 2:
Zero
 
Question Number 3:
In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department

鈥� Abrocitinib

鈥� Baricitinib

鈥� Dupilumab

鈥� Lebrikizumab

鈥� Tralokinumab


鈥� Upadacitinib

鈥� Nemolizumab

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen
 
Answer To Question 3:
Zero
 
Question Number 4:
How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

鈥� Dupilumab

鈥� Nemolizumab

 
Answer To Question 4:
Please see spreadsheet attached
Please see Attachments:
 
To return to the list of all the FOI requests please click here

Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

SA国际传媒, SA国际传媒 Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2026 SA国际传媒
Trust Values